+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Results for tag: "Hidradenitis Suppurativa Drug"

Hidradenitis Suppurativa Market Report 2025 - Product Thumbnail Image

Hidradenitis Suppurativa Market Report 2025

  • Report
  • February 2025
  • 200 Pages
  • Global
From
From
From
From
Hidradenitis Suppurativa - Pipeline Insight, 2024 - Product Thumbnail Image

Hidradenitis Suppurativa - Pipeline Insight, 2024

  • Clinical Trials
  • April 2024
  • 115 Pages
  • Global
From
Hidradenitis - Pipeline Insight, 2024 - Product Thumbnail Image

Hidradenitis - Pipeline Insight, 2024

  • Drug Pipelines
  • April 2024
  • 60 Pages
  • Global
From
Hidradenitis Suppurativa - Global Clinical Trials Review, 2024 - Product Thumbnail Image

Hidradenitis Suppurativa - Global Clinical Trials Review, 2024

  • Clinical Trials
  • October 2024
  • 183 Pages
  • Global
From
From
Hidradenitis Suppurativa (HS) - Epidemiology Forecast - 2032 - Product Thumbnail Image

Hidradenitis Suppurativa (HS) - Epidemiology Forecast - 2032

  • Report
  • September 2022
  • 95 Pages
  • Global
From
Hidradenitis - Epidemiology Forecast to 2032 - Product Thumbnail Image

Hidradenitis - Epidemiology Forecast to 2032

  • Report
  • January 2022
  • 60 Pages
  • Global
From
From
From
From
From
From
  • 18 Results (Page 1 of 1)
Loading Indicator

Hidradenitis Suppurativa (HS) is a chronic, inflammatory skin condition that affects the sweat glands and hair follicles. It is characterized by recurrent, painful, and inflamed nodules, abscesses, and scarring. Treatment for HS typically involves a combination of topical and systemic medications, including antibiotics, anti-inflammatory drugs, and immunosuppressants. The HS drug market is a subset of the larger dermatological drug market. It is composed of a variety of medications used to treat HS, including antibiotics, anti-inflammatory drugs, and immunosuppressants. These drugs are used to reduce inflammation, reduce pain, and prevent further progression of the disease. Some companies in the HS drug market include AbbVie, Amgen, AstraZeneca, Bristol-Myers Squibb, Eli Lilly, GlaxoSmithKline, Merck, Novartis, Pfizer, and Roche. Show Less Read more